Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: Insights from the EPIC, EPILOG, and EPISTENT trials.
Times cited: 83
Safety issues surrounding use of platelet GP IIb/IIIa antagonists: Reversibility and readministration.
European Heart Journal, Supplement.
Times cited: 8
Roundtable panel discussion: The role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes.
American Journal of Cardiology.
Times cited: 2
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor.
European Heart Journal.
Times cited: 29